Neuropilin-1 is required for TNature.comThe development of an anticancer immune response is often precluded by an immunosuppressive microenvironment, which can be created by the presence of large numbers of regulatory T cells (Treg). The findings of re… Continue reading
Nature.com |
Synthetic biology: Phagocytic protocells
Nature.com A synthetic colloidal system has been developed that mimics the biological process of phagocytosis — the ingestion of foreign material by certain cell types. As Stephen Mann and colleagues report in Nature Materials, synthetic ‘ecosystems’ such as … |
South China Morning Post |
Hong Kong biotech start-up claims world first in stem cell treatment of Alzheimer’s and Parkinson’s diseases
South China Morning Post But Yung claims his team is the first to successfully harvest stem cells directly from the brain and re-inject the developed neural cells back into a live subject, thereby artificially regenerating any cells which have died off, due to neurological … |
IMTJ |
The world’s first stem cell healthcare insurance plan
IMTJ Subsidiary CellPlan has developed the world’s first stem cell healthcare insurance plan and medical concierge service. The company has also developed a new commercial CellPlan medical opinion product- Your Expert Consultation that provides clients with … |
|
Engineering nature to prevent disease signals potential of synthetic biology
The Straits Times He is one of the 100 experts speaking at the Seventh International Meeting on Synthetic Biology, which opens on Tuesday (June 13). The event is co-organised by the National University of Singapore’s Synthetic Biology for Clinical and Technological … |
New Atlas |
The CRISPR controversy: Scientists skeptical over recent critical study
New Atlas Last month, a study was published claiming that the groundbreaking CRISPR-Cas9 gene-editing technique could potentially introduce hundreds of unintended mutations into an animal’s genome. Unsurprisingly, this study sent shockwaves through the … |
CNA Finance |
Gene Therapy for Localized Scleroderma Gets Rare Pediatric Designation
Rare Disease Report One month after receiving a Rare Pediatric Disease Designation for its gene therapy, FCX-007 to treat epidermolysis bullosa, the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation for FCX-013 to treat localized … Fibrocell’s gene therapy candidate FCX-013 nabs Rare Pediatric Disease Designation from FDA; shares ahead 9 …Seeking Alpha Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized SclerodermaGlobeNewswire (press release) FDA Designation A Boon For Fibrocell Science (FCSC)Economic Calendar CNA Finance (press release) all 12 news articles » |